- Home
- EIC vs YMAB Comparison
EIC vs YMAB Comparison
Compare EIC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- YMAB
- Stock Information
- Founded
- EIC N/A
- YMAB 2015
- Country
- EIC United States
- YMAB United States
- Employees
- EIC N/A
- YMAB N/A
- Industry
- EIC Finance/Investors Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- YMAB Health Care
- Exchange
- EIC Nasdaq
- YMAB Nasdaq
- Market Cap
- EIC 348.9M
- YMAB 386.7M
- IPO Year
- EIC 2019
- YMAB 2018
- Fundamental
- Price
- EIC $13.07
- YMAB $8.61
- Analyst Decision
- EIC
- YMAB Buy
- Analyst Count
- EIC 0
- YMAB 10
- Target Price
- EIC N/A
- YMAB $13.91
- AVG Volume (30 Days)
- EIC 151.9K
- YMAB 874.6K
- Earning Date
- EIC 11-13-2025
- YMAB 11-07-2025
- Dividend Yield
- EIC 11.95%
- YMAB N/A
- EPS Growth
- EIC N/A
- YMAB N/A
- EPS
- EIC 0.70
- YMAB N/A
- Revenue
- EIC $55,581,156.00
- YMAB $85,385,000.00
- Revenue This Year
- EIC $37.84
- YMAB N/A
- Revenue Next Year
- EIC $23.33
- YMAB $13.97
- P/E Ratio
- EIC $18.76
- YMAB N/A
- Revenue Growth
- EIC 56.39
- YMAB N/A
- 52 Week Low
- EIC $12.10
- YMAB $3.55
- 52 Week High
- EIC $16.71
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- EIC 40.46
- YMAB 81.21
- Support Level
- EIC $13.05
- YMAB $8.50
- Resistance Level
- EIC $13.45
- YMAB $8.56
- Average True Range (ATR)
- EIC 0.18
- YMAB 0.02
- MACD
- EIC -0.08
- YMAB -0.12
- Stochastic Oscillator
- EIC 2.07
- YMAB 100.00
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.